{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:49:22Z","timestamp":1788824962626,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ispen"},{"name":"Merz"},{"name":"Auspex"},{"name":"Diichi Sankyo Pharma"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Neurocrine, Sunovion Pharmaceuticals"},{"DOI":"10.13039\/100009427","name":"Acadia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009427","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Accorda"},{"name":"Cynapsus"},{"name":"Neuroderm"},{"name":"Prexton Therapeutics"},{"name":"Intec"},{"DOI":"10.13039\/100015453","name":"Adamas Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015453","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005616","name":"Allergan, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005616","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Biotie Therapies"},{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Civitas\/Acorda Therapeutics"},{"DOI":"10.13039\/100014427","name":"Dystonia Coalition","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014427","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001595","name":"Dystonia Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Huntington Study Group"},{"name":"Medtronic Neuromodulation"},{"DOI":"10.13039\/501100013116","name":"Merz Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013116","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000864","name":"Michael J Fox Foundation for Parkinson Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014593","name":"Neurocrine Biosciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014593","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013301","name":"Parkinson's Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013301","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Nuvelution"},{"DOI":"10.13039\/100014275","name":"Parkinson Study Group","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014275","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015364","name":"Prothena Biosciences Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015364","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Psyadon Pharmaceuticals, Inc."},{"DOI":"10.13039\/100015516","name":"Revance Therapeutics, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015516","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jns.2018.02.008","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T02:31:25Z","timestamp":1517884285000},"page":"10-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["The nosology of tardive syndromes"],"prefix":"10.1016","volume":"389","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-2997","authenticated-orcid":false,"given":"Karen","family":"Frei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6995-8936","authenticated-orcid":false,"given":"Daniel D.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Fahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jns.2018.02.008_bb0005","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.4088\/JCP.tv17016ah4c","article-title":"Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment","volume":"78","author":"Correll","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.008_bb0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0447.1964.tb05731.x","article-title":"Neurological symptoms in pharmacotherapy of psychoses","volume":"40","author":"Faurbye","year":"1964","journal-title":"Acta Psychiatr. Scand."},{"issue":"7","key":"10.1016\/j.jns.2018.02.008_bb0015","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s40265-016-0568-1","article-title":"Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia","volume":"76","author":"Vijayakumar","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jns.2018.02.008_bb0020","article-title":"An update on tardive dyskinesia: from phenomenology to treatment","volume":"3","author":"Waln","year":"2013","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"10.1016\/j.jns.2018.02.008_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2018.02.005","article-title":"Tardive syndrome","author":"Savitt","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.jns.2018.02.008_bb0030","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/BF00441188","article-title":"Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy","volume":"1","author":"Faurbye","year":"1960","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.jns.2018.02.008_bb0035","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/brain\/34.4.295","article-title":"Progressive lenticular degeneration: a familial nervous system disease associated with cirrhosis of the liver","volume":"34","author":"Wilson","year":"1912","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.jns.2018.02.008_bb0040","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/mds.23759","article-title":"Classification of movement disorders","volume":"26","author":"Fahn","year":"2011","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.jns.2018.02.008_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mds.26518","article-title":"The movement disorders journal 2016 and onward","volume":"31","author":"Obeso","year":"2016","journal-title":"Mov. Disord."},{"issue":"2 5","key":"10.1016\/j.jns.2018.02.008_bb0050","first-page":"737","article-title":"Extrapyramidal and diencephalic syndrome in the course of largactil and serpasil treatments","volume":"112","author":"Steck","year":"1954","journal-title":"Ann. Med. Psychol. (Paris)"},{"issue":"1","key":"10.1016\/j.jns.2018.02.008_bb0055","first-page":"19","article-title":"Chlorpromazine and neuroleptic treatments in psychiatry","volume":"17","author":"Delay","year":"1956","journal-title":"J. Clin. Exp. Psychopathol."},{"issue":"4","key":"10.1016\/j.jns.2018.02.008_bb0060","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00005053-195610000-00005","article-title":"Psychophysiologic aspects of the new chemotherapeutic drugs in psychiatry; some practical features of neuroleptics in order to screen new drugs","volume":"124","author":"Deniker","year":"1956","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.jns.2018.02.008_bb0065","series-title":"Handbook of Clinical Neurology","first-page":"246","article-title":"Drug-induced extrapyramidal syndromes","volume":"Vol 6","author":"Delay","year":"1968"},{"issue":"3","key":"10.1016\/j.jns.2018.02.008_bb0070","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/jama.1956.02970030032008","article-title":"Neurotoxic reactions resulting from chlorpromazine administration","volume":"161","author":"Hall","year":"1956","journal-title":"J. Am. Med. Assoc."},{"issue":"2","key":"10.1016\/j.jns.2018.02.008_bb0075","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1176\/ajp.113.2.115","article-title":"Complications of chlorpromazine therapy","volume":"113","author":"Cohen","year":"1956","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2018.02.008_bb0080","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1056\/NEJM195707252570405","article-title":"Complications from the use of tranquilizing drugs","volume":"257","author":"Hollister","year":"1957","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jns.2018.02.008_bb0085","first-page":"178","article-title":"Ein eigent\u00fcmliches Syndrom in oralen Bereich bei Megaphenappikation. [An unusual syndrome in the oral region caused by administration of megaphen]","volume":"27","author":"Kulenkampff","year":"1956","journal-title":"Nervenarzt"},{"issue":"6","key":"10.1016\/j.jns.2018.02.008_bb0090","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1176\/ajp.114.6.556","article-title":"An interesting reaction to a tranquilizer: tonic seizures with perphenazine (trilafon)","volume":"114","author":"Shanon","year":"1957","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.008_bb0095","first-page":"35","article-title":"Ein eigentumliches Syndrom im oralen Bereich bei Megaphen Applikation, [An unusual syndrome in the oral region caused by administration of megaphen]","volume":"28","author":"Sch\u00f4necker","year":"1957","journal-title":"Nervenarzt"},{"issue":"8","key":"10.1016\/j.jns.2018.02.008_bb0100","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1176\/ajp.124.8S.40","article-title":"Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature","volume":"124","author":"Crane","year":"1968","journal-title":"Am. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.jns.2018.02.008_bb0105","first-page":"550","article-title":"Paroxysmale Dyskinesen als Megaphenwirkung [Paroxysmal dyskinesia as the effect of megaphen]","volume":"28","author":"Sch\u00f4necker","year":"1957","journal-title":"Nervenarzt"},{"issue":"4","key":"10.1016\/j.jns.2018.02.008_bb0110","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJM195907232610404","article-title":"Clinical indications and toxicity of prolonged perphenazine therapy","volume":"261","author":"Ayd","year":"1959","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2018.02.008_bb0115","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJM196102092640609","article-title":"Complications from psychotherapeutic drugs","volume":"264","author":"Hollister","year":"1961","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2018.02.008_bb0120","first-page":"751","article-title":"Quatre cas de dyskinesie facio-bucco-linguo-masticatrice a l'evolution prolongee secondaire a un traitement par les neuroleptiques. [4 cases of facio-bucco-linguo-masticatory dyskinesis of prolonged development following treatment with neuroleptics]","volume":"100","author":"Sigwald","year":"1959","journal-title":"Rev. Neurol. (Paris)"},{"issue":"2","key":"10.1016\/j.jns.2018.02.008_bb0125","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4088\/JCP.v66n0216","article-title":"Historical comments on tardive dyskinesia: a neurologist's perspective","volume":"66","author":"Paulson","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.008_bb0130","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1176\/ajp.118.6.551","article-title":"Tetrabenacine treatment in persisting dyskinesia caused by psychopharmaca","volume":"118","author":"Brandrup","year":"1961","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.008_bb0135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00005053-196207000-00009","article-title":"Chronic involuntary movements induced by phenothiazines","volume":"135","author":"Druckman","year":"1962","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.jns.2018.02.008_bb0140","first-page":"758","article-title":"An apparently irreversible syndrome of abnormal movements following phenothiazine medication","volume":"57","author":"Hunter","year":"1964","journal-title":"Proc. R. Soc. Med."},{"key":"10.1016\/j.jns.2018.02.008_bb0145","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/jnnp.27.3.219","article-title":"A syndrome of abnormal movements and dementia in leucotomized patients treated with phenothiazines","volume":"27","author":"Hunter","year":"1964","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7383","key":"10.1016\/j.jns.2018.02.008_bb0150","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0140-6736(65)91590-4","article-title":"Persistent oral dyskinesia in treatment with phenothiazine derivatives","volume":"1","author":"Evans","year":"1965","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jns.2018.02.008_bb0155","first-page":"167","article-title":"Drug induced dystonia tarda: treatment with L-dopa","volume":"34","author":"Keegan","year":"1973","journal-title":"Dis. Nerv. Syst."},{"issue":"12","key":"10.1016\/j.jns.2018.02.008_bb0160","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1212\/WNL.32.12.1335","article-title":"Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs","volume":"32","author":"Burke","year":"1982","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2018.02.008_bb0165","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1056\/NEJM197807272990420","article-title":"Tardive dyskinesia may be only akathisia","volume":"299","author":"Fahn","year":"1978","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jns.2018.02.008_bb0170","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00002826-198306000-00009","article-title":"Treatment of tardive dyskinesia: use of dopamine-depleting agents","volume":"6","author":"Fahn","year":"1983","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.jns.2018.02.008_bb0175","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mds.870040208","article-title":"Tardive akathisia: an analysis of clinical features and response to open therapeutic trials","volume":"4","author":"Burke","year":"1989","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2018.02.008_bb0180","series-title":"Principles and Practice of Movement Disorders","first-page":"430","author":"Fahn","year":"2011"},{"issue":"18","key":"10.1016\/j.jns.2018.02.008_bb0185","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","article-title":"Dopamine depleters in the treatment of hyperkinetic movement disorders","volume":"17","author":"Jankovic","year":"2016","journal-title":"Expert. Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.jns.2018.02.008_bb0190","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0022-3565(25)33621-9","article-title":"Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain","volume":"225","author":"Reches","year":"1983","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.jns.2018.02.008_bb0195","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ana.410170217","article-title":"Tetrabenazine induces acute dystonic reactions","volume":"17","author":"Burke","year":"1985","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.jns.2018.02.008_bb0200","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/WNL.31.8.1022","article-title":"Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease","volume":"31","author":"Burke","year":"1981","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2018.02.008_bb0205","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archpsyc.1982.04290040080012","article-title":"Incidence and severity of tardive dyskinesia increase with age","volume":"39","author":"Johnson","year":"1982","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4 Suppl","key":"10.1016\/j.jns.2018.02.008_bb0210","first-page":"31S","article-title":"The natural history of tardive dyskinesia","volume":"8","author":"Gardos","year":"1988","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.jns.2018.02.008_bb0215","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archpsyc.1982.04290040080014","article-title":"Research diagnoses for tardive dyskinesia","volume":"39","author":"Schooler","year":"1982","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.jns.2018.02.008_bb0220","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40265-016-0566-3","article-title":"Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia","volume":"76","author":"Vijayakumar","year":"2016","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.jns.2018.02.008_bb0225","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.870010305","article-title":"Natural history and treatment of tardive dystonia","volume":"1","author":"Kang","year":"1986","journal-title":"Mov. Disord."},{"issue":"Pt 11","key":"10.1016\/j.jns.2018.02.008_bb0230","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/brain\/121.11.2053","article-title":"The natural history of tardive dystonia. A long-term follow-up study of 107 cases","volume":"121","author":"Kiriakakis","year":"1998","journal-title":"Brain"},{"issue":"703","key":"10.1016\/j.jns.2018.02.008_bb0235","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/pgmj.60.703.359","article-title":"Persistent akathisia associated with early tardive dyskinesia","volume":"60","author":"Barnes","year":"1984","journal-title":"Postgrad. Med. J."},{"issue":"2","key":"10.1016\/j.jns.2018.02.008_bb0240","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/mds.870100224","article-title":"The classification of akathisia","volume":"10","author":"Sachdev","year":"1995","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.jns.2018.02.008_bb0245","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/ana.410130420","article-title":"Persistent akathisia following neuroleptic withdrawal","volume":"13","author":"Weiner","year":"1983","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2018.02.008_bb0250","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1212\/WNL.28.10.1064","article-title":"Gilles de la Tourette syndrome after long-term chlorpromazine therapy","volume":"28","author":"Klawans","year":"1978","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jns.2018.02.008_bb0255","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/mds.870100613","article-title":"Tardive tourettism after exposure to neuroleptic therapy","volume":"10","author":"Bharucha","year":"1995","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.jns.2018.02.008_bb0260","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/YIC.0b013e32834aa924","article-title":"Tardive Tourette-like syndrome: a systematic review","volume":"26","author":"Fountoulakis","year":"2011","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jns.2018.02.008_bb0265","doi-asserted-by":"crossref","first-page":"422","DOI":"10.5334\/tohm.287","article-title":"Deutetrabenazine in tics associated with tourette syndrome","volume":"6","author":"Jankovic","year":"2016","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"1","key":"10.1016\/j.jns.2018.02.008_bb0270","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mds.870070110","article-title":"Tardive tremor","volume":"7","author":"Stacy","year":"1992","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.jns.2018.02.008_bb0275","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/mds.870120533","article-title":"Tardive tremor","volume":"12","author":"Storey","year":"1997","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.jns.2018.02.008_bb0280","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/mds.870130517","article-title":"A case of tardive tremor successfully treated with clozapine","volume":"13","author":"Delecluse","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2018.02.008_bb0285","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-11-2011-5156","article-title":"Sensory trick with metoclopramide-associated tardive tremor","author":"Shprecher","year":"2012","journal-title":"BMJ Case Rep."},{"issue":"1","key":"10.1016\/j.jns.2018.02.008_bb0290","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/WNF.0000000000000061","article-title":"Tetrabenazine for tardive tremor in elderly adults: a prospective follow-up study","volume":"38","author":"Kertesz","year":"2015","journal-title":"Clin. Neuropharmacol."},{"issue":"8528","key":"10.1016\/j.jns.2018.02.008_bb0295","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0140-6736(87)92042-3","article-title":"Tardive myoclonus","volume":"1","author":"Tominaga","year":"1987","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jns.2018.02.008_bb0300","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/mds.870020408","article-title":"Tardive myoclonus","volume":"2","author":"Little","year":"1987","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.jns.2018.02.008_bb0305","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1176\/ajp.146.6.802a","article-title":"Tardive dyskinesia with complaints of pain","volume":"146","author":"Hierholzer","year":"1989","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.jns.2018.02.008_bb0310","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1212\/WNL.44.11.2115","article-title":"Oral and genital tardive pain syndromes","volume":"44","author":"Ford","year":"1994","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jns.2018.02.008_bb0315","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1212\/WNL.45.11.2113","article-title":"Tardive pain","volume":"45","author":"Montagna","year":"1995","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2018.02.008_bb0320","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/WNF.0b013e31818ddbc4","article-title":"Botulinum toxin in painful tardive dyskinesia","volume":"32","author":"Tschopp","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2018.02.008_bb0325","series-title":"Principles and Practice of Movement Disorders","first-page":"427","author":"Fahn","year":"2011"},{"issue":"7","key":"10.1016\/j.jns.2018.02.008_bb0330","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.jns.2018.02.008_bb0335","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.parkreldis.2014.03.024","article-title":"Motor and non-motor features of Parkinson's disease that predict persistent drug-induced Parkinsonism","volume":"20","author":"Morley","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"issue":"2","key":"10.1016\/j.jns.2018.02.008_bb0340","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/jnnp.60.2.213","article-title":"Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs","volume":"60","author":"Bocola","year":"1996","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.jns.2018.02.008_bb0345","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nrl.2012.05.005","article-title":"Diagnostic accuracy of 123 I-FP-CIT SPECT in diagnosing drug-induced parkinsonism: a prospective study","volume":"28","author":"Olivares Romero","year":"2013","journal-title":"Neurologia"},{"issue":"4","key":"10.1016\/j.jns.2018.02.008_bb0350","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.20748","article-title":"[123I]-FP\/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease","volume":"21","author":"Lorberboym","year":"2006","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.jns.2018.02.008_bb0355","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/archneur.1982.00510220042009","article-title":"Reversible drug-induced parkinsonism. Clinicopathologic study of two cases","volume":"39","author":"Rajput","year":"1982","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2018.02.008_bb0360","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/mds.10202","article-title":"Clinical correlates of the pathology underlying parkinsonism: a population perspective","volume":"17","author":"Bower","year":"2002","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.jns.2018.02.008_bb0365","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/mds.26467","article-title":"Neuroleptic-induced parkinsonism: clinicopathological study","volume":"31","author":"Shuaib","year":"2016","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.jns.2018.02.008_bb0370","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/14737175.2017.1386556","article-title":"Valbenazine for the treatment of tardive dyskinesia","volume":"17","author":"Muller","year":"2017","journal-title":"Expert. Rev. Neurother."},{"issue":"8","key":"10.1016\/j.jns.2018.02.008_bb0375","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"4","author":"Anderson","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"21","key":"10.1016\/j.jns.2018.02.008_bb0380","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study","volume":"88","author":"Fernandez","year":"2017","journal-title":"Neurology"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18300662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18300662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T18:33:28Z","timestamp":1751308408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X18300662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":76,"alternative-id":["S0022510X18300662"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2018.02.008","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The nosology of tardive syndromes","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2018.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}